EC Clinical and Medical Case Reports

We present the case of a 57-year-old male patient diagnosed with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The initial diagnosis included clinical findings such as hepatomegaly and splenomegaly, accompanied by extreme leukocytosis. Molecular studies confirmed the presence of the Philadelphia chromosome, with cytogenetic studies showing resistance to tyrosine kinase inhibitors such as dasatinib. The patient received multiple treatments, including imatinib, dasatinib, and later bosutinib. Complete blood counts and bone biopsies showed infiltration of lymphoid blasts and hematologic complications such as neutropenia and severe anemia. During follow-up, no hematologic or molecular response was observed. Management was limited by the patient's refusal to receive intensive chemotherapy and the lack of availability of allogeneic transplantation in Honduras.

 Keywords: Acute Lymphoblastic Leukemia; Philadelphia Chromosome; Blastosis; Tyrosine Kinase Inhibitors; Neutropenia

1. Chilean Ministries of Health. Clinical protocol, Philadelphia-positive acute lymphoblastic leukemia in patients over 15 years of age. Adult cancer program 2020 (2021).
2. Benavente Rafael., et al. “Intensive chemotherapy associated with imatinib in adult acute lymphoblastic leukemia, Philadelphia positive. Experience in a public hospital”. Journal of Medicine of Chile (2021).
3. Hamilton Betty Ky., et al. “Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia”. Biology of Blood and Marrow Transplantation7 (2019): 1117-1121.
4. March-Castillejo Mercè., et al. “Cancer prevention recommendations. PAPPS Update 2022”. Primary Care (2022).
5. Adele F. “Current treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia”. Hematology American Society of Hematology Education Program (2011).
6. Aguilera Dolly G., et al. “Dasatinib in chronic myeloid leukemia: a review”. Therapeutics and Clinical Risk Management2 (2019): 281-289.
7. Kaleem Bushra., et al. “Impact of T315I mutation on prognosis in chronic myeloid leukemia”. Advances in Laboratory Medicine4 (2024): 412-417.
8. McCloskey James K., et al. “Blinatumomab in combination with tyrosine kinase inhibitors safely and effectively induces rapid, deep, and durable molecular responses in relapsed and refractory Philadelphia positive acute leukemias”. Blood1 (2019): 3812.
9. Kruse Aaron., et al. “Minimal residual disease detection in acute lymphoblastic leukemia”. International Journal of Molecular Sciences3 (2020): 1054.